NASDAQ:JYNT - Joint Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.33 +0.88 (+6.09 %) (As of 03/22/2019 01:54 AM ET)Previous Close$14.45Today's Range$14.45 - $15.5552-Week Range$5.79 - $15.55Volume303,800 shsAverage Volume90,747 shsMarket Capitalization$210.68 millionP/E Ratio383.25Dividend YieldN/ABeta0.75 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of December 31, 2018, the company operated 442, including 394 franchised clinics, and 48 corporate owned or managed clinics. The company was founded in 2010 and is headquartered in Scottsdale, Arizona. Receive JYNT News and Ratings via Email Sign-up to receive the latest news and ratings for JYNT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Patent owners & lessors Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:JYNT Previous Symbol CUSIPN/A CIK1612630 Webwww.thejoint.com Phone480-245-5960Debt Debt-to-Equity RatioN/A Current Ratio1.34 Quick Ratio1.34Price-To-Earnings Trailing P/E Ratio383.25 Forward P/E Ratio76.65 P/E Growth6.76 Sales & Book Value Annual Sales$31.79 million Price / Sales6.63 Cash Flow$0.1733 per share Price / Cash Flow88.46 Book Value$0.17 per share Price / Book90.18Profitability EPS (Most Recent Fiscal Year)$0.04 Net Income$250,000.00 Net Margins0.80% Return on Equity39.20% Return on Assets2.97%Miscellaneous EmployeesN/A Outstanding Shares13,743,000Market Cap$210.68 million Next Earnings Date5/9/2019 (Estimated) OptionableNot Optionable Joint (NASDAQ:JYNT) Frequently Asked Questions What is Joint's stock symbol? Joint trades on the NASDAQ under the ticker symbol "JYNT." How were Joint's earnings last quarter? Joint Corp (NASDAQ:JYNT) announced its earnings results on Thursday, March, 7th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.05 by $0.01. The firm earned $9.07 million during the quarter, compared to analysts' expectations of $8.65 million. Joint had a return on equity of 39.20% and a net margin of 0.80%. View Joint's Earnings History. When is Joint's next earnings date? Joint is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Joint. What guidance has Joint issued on next quarter's earnings? Joint issued an update on its FY 2019 earnings guidance on Thursday, March, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $40.068-41.976 million, compared to the consensus revenue estimate of $38.75 million. What price target have analysts set for JYNT? 4 equities research analysts have issued 12-month price objectives for Joint's stock. Their forecasts range from $12.00 to $20.00. On average, they expect Joint's stock price to reach $16.25 in the next twelve months. This suggests a possible upside of 6.0% from the stock's current price. View Analyst Price Targets for Joint. What is the consensus analysts' recommendation for Joint? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Joint in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Joint. What are Wall Street analysts saying about Joint stock? Here are some recent quotes from research analysts about Joint stock: 1. According to Zacks Investment Research, "The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company's plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. " (3/20/2019) 2. Maxim Group analysts commented, "Yesterday after the market close, JYNT reported 4Q18 results that beat estimates across the board and issued better-than-expected 2019 financial guidance. The company opened 22 franchise clinics in 4Q18, versus our estimate of 15, and closed two, for a total of 394. Its corporate clinic count remained at 48. We raise our 2019 and 2020 revenue estimates, as well as out-year top- and bottom-line numbers, as we expect a significantly higher rate of franchise and corporate clinic openings going forward. As a result, we increase our price target to $18, from $11." (3/8/2019) Has Joint been receiving favorable news coverage? News stories about JYNT stock have trended neutral on Friday, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Joint earned a coverage optimism score of 0.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the company's share price in the next several days. Who are some of Joint's key competitors? Some companies that are related to Joint include Digital Turbine (APPS), Acacia Research (ACTG), Liberty Tax (TAXA), Quarterhill (QTRH), Finjan (FNJN), Research Frontiers (REFR), XCel Brands (XELB), Marathon Patent Group (MARA), Health Discovery (HDVY), ARC Group (ARCK), MGT Capital Investments (MGTI), Spherix (SPEX), XpresSpa Group (XSPA), American Restaurant Partners LP Class A Partnership Units (ICTPU) and Patriot Scientific (PTSC). What other stocks do shareholders of Joint own? Based on aggregate information from My MarketBeat watchlists, some companies that other Joint investors own include Novavax (NVAX), Rite Aid (RAD), Allena Pharmaceuticals (ALNA), Synergy Pharmaceuticals (SGYP), New Residential Investment (NRZ), Applied Materials (AMAT), Veracyte (VCYT), Alibaba Group (BABA), Bausch Health Companies (BHC) and Weatherford International (WFT). Who are Joint's key executives? Joint's management team includes the folowing people: Mr. Peter D. Holt, CEO, Pres & Director (Age 60)Mr. Jake Singleton, CFO & Corp. ControllerMr. Jorge Armenteros, VP of OperationsDr. James Edwards, Chief Chiropractic & Compliance OfficerMr. Craig P. Colmar, Sec. (Age 66) When did Joint IPO? (JYNT) raised $20 million in an IPO on Tuesday, November 11th 2014. The company issued 3,000,000 shares at $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager. Who are Joint's major shareholders? Joint's stock is owned by a number of of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (9.94%), Nantahala Capital Management LLC (8.22%), Skylands Capital LLC (4.19%), Acadian Asset Management LLC (1.39%), Geode Capital Management LLC (0.45%) and Geode Capital Management LLC (0.45%). Company insiders that own Joint stock include Glenhill Advisors Llc, James H Amos Jr, John P Meloun, Peter D Holt and Ronald V Davella. View Institutional Ownership Trends for Joint. Which major investors are selling Joint stock? JYNT stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Macquarie Group Ltd., Skylands Capital LLC, Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have sold Joint company stock in the last year include John P Meloun and Ronald V Davella. View Insider Buying and Selling for Joint. Which major investors are buying Joint stock? JYNT stock was bought by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Globeflex Capital L P, Alambic Investment Management L.P., Acadian Asset Management LLC and Northern Trust Corp. Company insiders that have bought Joint stock in the last two years include James H Amos Jr, John P Meloun and Peter D Holt. View Insider Buying and Selling for Joint. How do I buy shares of Joint? Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Joint's stock price today? One share of JYNT stock can currently be purchased for approximately $15.33. How big of a company is Joint? Joint has a market capitalization of $210.68 million and generates $31.79 million in revenue each year. The company earns $250,000.00 in net income (profit) each year or $0.04 on an earnings per share basis. What is Joint's official website? The official website for Joint is http://www.thejoint.com. How can I contact Joint? Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected] MarketBeat Community Rating for Joint (NASDAQ JYNT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 177 (Vote Outperform)Underperform Votes: 167 (Vote Underperform)Total Votes: 344MarketBeat's community ratings are surveys of what our community members think about Joint and other stocks. Vote "Outperform" if you believe JYNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JYNT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/22/2019 by MarketBeat.com StaffFeatured Article: Trading Stocks - What are percentage gainers?